Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:SYK
Stryker Corp. (SYK)
307.00
-0.80 (0.26%)
as of Jun 18, 2026, 8:52:16 pm Market Open.
184 watching
Financials 
Technical Analysis 0
TOP PICK
TOP PICK
It makes artificial joints and all kinds of specialized medical equipment. It is focused on many areas including hips, knees, ankles, etc. He especially likes the robotic assisted surgery component. Buy 16 Hold 12 Sell 2
Paul MacDonaldOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Mar 16/22, Up 0.1%)
Fell a lot through Covid decline in elective surgeries. Great place to be over the long term. Aging demographics in its favour.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Mar 16/22, Down 2%) Great business. Backlog in elective surgeries due to Covid will lead to good earnings growth going forward. Good growth internationally. Demographic play. Loyal customer base. Great medical device story.
Paul Harris, CFAOwned
biotechnologypharmaceutical
DON'T BUY
SYK vs. ISRG ISRG reported last night, market not too happy, but this is short term. At 50x PE, ISRG is expensive on any traditional valuation, yet has no real competition in robotic surgery market. ISRG has a great franchise and platform, and will grow earnings over next decade 200-300%. Because SYK is in hips and knees, it's not in direct competition. SYK's space is more competitive, but also has much lower valuation. With Covid shortages ending, SYK could see some upside next 3-4 months.
Jamie Murray No
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Nov 02/21, Down 19%) Good growth internationally. Demand increasing with aging population. Great balance sheet, opportunity to make acquisitions. Trades at 22x. Pandemic backlog of elective surgeries offsets inflationary costs. Supply chain difficulties persist. He'd buy here. Yield is 1.4%.
Paul Harris, CFAOwned
biotechnologypharmaceutical
HOLD
Medical supply companies impacted by Covid-19, staffing shortages and inflation.
Need for healthcare services not going away.
Likes business area, but not investing in Stryker.
Other companies with better prospects.
Jamie Murray No
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Aug 24/21, Down 23%) It is a medical device company and had a tough time over Covid. Now there is a big backlog in elective surgeries so much more of its products will be needed. 71% of business is from the U.S. where there is lots of room to grow globally. Also doctors doing the surgeries tend to stay with the same products. Lots of free cash flow.
Paul Harris, CFAOwned
biotechnologypharmaceutical
BUY
They make medical devices. They bought a medical company focused on hands. Again demographics will increase demand for knee and hip replacements. Also, doctors seldom change device-makers, so they will stick with Stryker. They have little presence outside the U.S. so there are opportunities for growth there. Also, there's a backlog in elective surgeries.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 12/21, Down 4%) Elective surgeries shut down due to Covid, so now there's a backlog. Supply chain issues. Employment issues. They can get through these headwinds. Acquisition and integration going well. Digitization being integrated into services, including valuable patient data.
Paul Harris, CFAOwned
biotechnologypharmaceutical
HOLD
Robotic-assisted surgery has been a large growth area. Multiple compressed significantly. Elective surgeries accelerating, a positive for the business. Shipping and specialty metal constraints are priced in. Fairly priced. Hold through volatility. Quality company, well run. Look at ROE and ROE growth. Aim for a PE multiple of 21x.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Apr 06/21, Up 13%) Couple of tough years with Covid. Huge backlog, demographic tailwinds, improve people's quality of life. Pre-eminent company in this area. Can upsell new products coming out.
Paul Harris, CFAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Medical device business very strong - high growth area.
Healthcare sector demand not slowing down.
Aging baby boomer population will require further healthcare.
Need for increased healthcare tech.